|
|
Article: U.S. Patent Disclosures.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Arius Research Inc., of Toronto, was granted U.S. Patent No. 7,189,397, titled "Cytotoxicity mediation of cells evidencing surface expression of CD44," relating to its CD44 Stem Cell Program, and No. 7,195,764, titled "Cancerous Disease Modifying Antibodies," which covers the use of antibodies against CD59. The company also received U.S. Patent No. 7,252,821, covering the use of the ARH460-16-2 antibody and the use of the antibody in breast cancer. Separately, Arius was granted two additional patents for antibodies: U.S. Patent No. 7,256,272, which covers composition of matter claims for a CD63-targeting antibody and clone, and U.S. Patent No. 7,256,271, which contains ...
Related newspaper, magazine, and journal articles:
|
|
Article: U.S. Patent Disclosures.(Public notice)
BIOWORLD Today;
January 14, 2008 ;
700+ words
... ... was issued U.S. Patent No. 7,297,480, titled "Method for Detection ... was granted U.S. Patent No. 7,268,116, titled "Methods and Compositions ... notice of allowance for a patent, titled "Phase Displayed Trp Cage ...
|
|